Read twice and referred to the Committee on Finance.
The Maximizing Opioid Recovery Emergency Savings (MORE Savings) Act directs Medicare, Medicaid, and private health plans to increase affordable access to evidence-based treatments for opioid use disorder (OUD) by eliminating cost-sharing for certain drugs, behavioral health services, and recovery support services. It requires the CMS Innovation Center to implement, within six months of enactment, a 15-state Medicare model that eliminates coinsurance, copayments, and deductibles under Medicare Parts B and D (and Medicare Advantage as applied) for opioid-related medications, behavioral health care, and recovery supports; that model cannot be terminated or modified for the first five years.
Whether eliminating cost-sharing for OUD treatment is primarily a public-health benefit (liberal/centrist) or an undue mandate that will raise premiums and expand federal reach (conservative).
Relative to its intended legislative type, this bill is a clearly framed substantive policy change that uses direct statutory amendments to mandate zero cost-sharing for opioid treatment services across multiple coverage systems and to create/modify a Medicare model and Medicaid matching.
The Maximizing Opioid Recovery Emergency Savings (MORE Savings) Act directs Medicare, Medicaid, and private health plans to increase affordable access to evidence-based treatments for opioid use disorder (OUD) by eliminating cost-sharing for certain drugs, behavioral health services, and recovery support services.
It requires the CMS Innovation Center to implement, within six months of enactment, a 15-state Medicare model that eliminates coinsurance, copayments, and deductibles under Medicare Parts B and D (and Medicare Advantage as applied) for opioid-related medications, behavioral health care, and recovery supports; that model cannot be terminated or modified for the first five years.
The bill amends federal insurance law (PHSA), ERISA, and the Internal Revenue Code to require group and individual plans and employer plans to cover and not impose cost-sharing for OUD drugs, overdose reversal drugs, behavioral health services (including licensed non-hospital residential treatment), and certain recovery support services, effective for plan years beginning on or after January 1, 2027.
On content alone, the bill addresses a widely recognized public‑health problem and contains elements that could attract bipartisan support (e.g., support for MAT, peer services, overdose reversal). However, it enacts broad federal mandates on private insurance, creates substantial federal fiscal exposure (90% FMAP for certain services; eliminated cost‑sharing costs), and makes complex cross‑statutory changes—factors that historically raise opposition from fiscal conservatives, insurers, and employers and complicate floor dynamics. The inclusion of pilot/state‑option features and delayed effective dates improve prospects, but the Senate’s procedural constraints and likely interest‑group pushback reduce the overall chance of enactment based solely on textual features.
Relative to its intended legislative type, this bill is a clearly framed substantive policy change that uses direct statutory amendments to mandate zero cost-sharing for opioid treatment services across multiple coverage systems and to create/modify a Medicare model and Medicaid matching. The bill locates its changes precisely within existing statutes and supplies several implementation triggers and limited fiscal acknowledgment (enhanced FMAP).
Whether eliminating cost-sharing for OUD treatment is primarily a public-health benefit (liberal/centrist) or an undue mandate that will raise premiums and expand federal reach (conservative).
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether eliminating cost-sharing for OUD treatment is primarily a public-health benefit (liberal/centrist) or an undue mandate that will raise premiums and expand federal reach (conservative).
This persona would likely view the bill positively as a strong federal step to remove financial barriers to evidence-based opioid treatment and to expand recovery services, especially for Medicare beneficiaries and low-income Medicaid enrollees.
They would welcome elimination of copays and deductibles for medication-assisted treatment (MAT), naloxone, behavioral health services, and peer support, seeing it as aligned with treatment-as-healthcare and harm-reduction goals.
They would note the Medicaid FMAP boost and the CMS model as mechanisms to expand access quickly, especially in high-need rural and high-overdose states.
A pragmatic centrist would generally view the bill favorably for removing cost barriers to evidence-based treatments and for targeting resources toward high-overdose and rural areas, but would want clearer fiscal offsets, implementation details, and evaluation plans.
They would appreciate the use of a CMS Innovation Center model and a 5-year no-termination period as a chance to test effectiveness, while wanting metrics, accountability, and cost estimates.
They would be cautious about federal mandates on private plans (concern about premium impacts) and the administrative complexity of adding new no-cost services.
A mainstream conservative would likely be skeptical of the bill’s federal mandates on private and employer-sponsored health plans and concerned about new costs being shifted to insurers, employers, and ultimately consumers.
They would view federal prescription of coverage and elimination of cost-sharing as an expansion of federal authority into employer benefit design and worry about unintended premium increases or administrative burdens.
They might support targeted measures like wider naloxone access or proven MAT programs, but would prefer state flexibility, narrower federal mandates, and protections against increased federal spending and mandates on private actors.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill addresses a widely recognized public‑health problem and contains elements that could attract bipartisan support (e.g., support for MAT, peer services, overdose reversal). However, it enacts broad federal mandates on private insurance, creates substantial federal fiscal exposure (90% FMAP for certain services; eliminated cost‑sharing costs), and makes complex cross‑statutory changes—factors that historically raise opposition from fiscal conservatives, insurers, and employers and complicate floor dynamics. The inclusion of pilot/state‑option features and delayed effective dates improve prospects, but the Senate’s procedural constraints and likely interest‑group pushback reduce the overall chance of enactment based solely on textual features.
The bill has not accumulated any surfaced votes yet.
Whether eliminating cost-sharing for OUD treatment is primarily a public-health benefit (liberal/centrist) or an undue mandate that will ra…
On content alone, the bill addresses a widely recognized public‑health problem and contains elements that could attract bipartisan support…
Relative to its intended legislative type, this bill is a clearly framed substantive policy change that uses direct statutory amendments to mandate zero cost-sharing for opioid treatment services across multiple coverag…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.